Table 2 Clinical characteristics of HIV-seropositive patients with access to HAART (n = 10). TNM: TNM classification of malignant tumors, HAART: Highly active anti-retroviral treatment. * indicates: HAART was started with or immediately before RT. CDC: HIV disease stage (Centers for Disease Control). RT: Radiotherapy. HDR: High-dose-rate brachytherapy. CT: Chemotherapy. 5-FU: Fluorouracil. MMC: Mitomycin-C. f/u: Follow-up. APR: Abdomino-perineal resection. NED: No evidence of disease. MD: Moist desquamation. TC-penia: Thrombocytopenia. 1 = stavudin, 2 = didanosin, 3 = lamivudin, 4 = zidovudin, 5 = efavirenz, 6 = abacavir, 7 = ritonavir, 8 = nelfinavir, 9 = amprenavir.
TNM | CDC | CD4 | HAART | RT (Gy) | RT duration (days) | CT (mg) 5-FU/MMC | acute toxicity | chronic side effects | recurrence | f/u |
|---|---|---|---|---|---|---|---|---|---|---|
T1N0M0 | C3 | 80 | 1, 2, 7 | 54 | 45 | 16100 | incontinence I° | local | APR, recurrence | |
T3N0M0 | C3 | 847 | 1, 3 | 59.4 | 45 | 13600/34 | MD | none | NED | |
T1N0M0 | C3 | 64 | 2, 3, 6, 9 | 59.4 | 48 | 15400/15 | MD, Tc-penia | skin III° | none | NED |
T3N0M0 | A3 | 88 | 3, 4, 5 | 59.4 | 47 | 14400/30 | incontinence I° | none | NED | |
T2N0M0 | A1 | 591 | 1, 2, 7 | 54 | 60 | 11250/40 | loco-regional | palliation, failed | ||
T2N0M0 | B3 | 354 | 1, 2, 8 * | 59.4 | 37 | none | MD | none | NED | |
T2N2M0 | C3 | 105 | 3, 4, 8 * | 59.4 | 47 | none | none | NED | ||
T2N0M0 | C3 | 262 | 1, 3, 8 | 59.4 | 56 | 6800/20 | Tc-penia | inguinal | failed | |
T2N0M0 | C3 | 190 | 3, 4, 6 | 55.8 | 43 | none | local | APR, NED | ||
T2N0M0 | A2 | 370 | 3, 4, 5 | 55.5 | 46 | 15520/19 | Tc-penia | none | NED |